REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 6th, 2020 • Selecta Biosciences Inc • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 11, 2020, is entered into by and between Selecta Biosciences, Inc., a Delaware corporation (the “Company”), and the “Purchaser” named in that certain Share Purchase Agreement, dated as of June 11, 2020, by and between the Company and Purchaser (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
LICENSE AND DEVELOPMENT AGREEMENT by and between SELECTA BIOSCIENCES, INC. and SWEDISH ORPHAN BIOVITRUM AB (PUBL)License and Development Agreement • August 6th, 2020 • Selecta Biosciences Inc • Pharmaceutical preparations • New York
THIS LICENSE AND DEVELOPMENT AGREEMENT (“Agreement”) dated as of June 11, 2020 (the “Execution Date”) is by and between SELECTA BIOSCIENCES, INC., a Delaware corporation having its principal place of business at 65 Grove Street, Watertown, MA 02472 (“Licensor”) and SWEDISH ORPHAN BIOVITRUM AB (publ), a Swedish public company having its principal place of business at SE-112 76 Stockholm, Sweden (“Licensee”). Licensor and Licensee are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
STOCK PURCHASE AGREEMENTStock Purchase Agreement • August 6th, 2020 • Selecta Biosciences Inc • Pharmaceutical preparations • Delaware
THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of June 11, 2020, is entered into by and between Selecta Biosciences, Inc., a Delaware corporation (the “Company”), and Swedish Orphan Biovitrum AB (publ), a Swedish public limited liability company (the “Purchaser”).
FIFTH AMENDMENTExclusive Patent License Agreement • August 6th, 2020 • Selecta Biosciences Inc • Pharmaceutical preparations
This Fifth Amendment, effective as of the date set forth above the signatures of the parties below (“Amendment Effective Date”), amends the Exclusive Patent License Agreement effective November 25, 2008, as amended by a First Amendment dated January 12, 2010, a Second Amendment dated August 29, 2013, a Third Amendment dated November 18, 2016, and a Fourth Amendment dated December 13, 2019 (the “License Agreement”) between the Massachusetts Institute of Technology, a Massachusetts corporation having its principal office at 77 Massachusetts Avenue, Cambridge, Massachusetts 02139 (“MIT”), and Selecta Biosciences, Inc., a Delaware corporation, with a principal place of business at 65 Grove Street, Watertown, MA 02472 (“COMPANY”).
